Navigation Links
Varian Medical Systems Equips International Oncology's First Comprehensive Cancer Center in India
Date:6/16/2010

NOIDA, India, June 16 /PRNewswire-FirstCall/ -- The first in a planned series of new radiotherapy centers aimed at improving access to advanced treatments for millions of Indian cancer patients has been officially opened in Noida. Fortis International Oncology Centre, a joint initiative between International Oncology and Fortis Healthcare, is equipped with advanced radiotherapy equipment and software from Varian Medical Systems (NYSE: VAR).

Dignitaries at yesterday's official inauguration ceremony – including Dr. Montek Singh Ahluwalia, the deputy chairman of the Planning Commission of India – were given a tour of the facility to see Varian's Trilogy® medical linear accelerator in action. Trilogy, capable of delivering a full range of advanced radiotherapy and radiosurgery techniques including RapidArc® radiotherapy, has been operational at Noida for four months.

The new center is among the first in India to offer RapidArc, which enables clinicians to deliver a highly-precise image-guided intensity-modulated radiotherapy (IMRT) treatment in as little as one or two revolutions of the treatment machine around the patient, much faster than is possible with conventional IMRT. Faster treatments allow for greater precision, since there is less chance of patient or tumor movement during treatment delivery and, with less time on the treatment couch, also allow for greater patient comfort.

Pradeep K. Jaisingh, managing director and CEO of International Oncology Services Pvt Ltd, says, "There is a tremendous gap in advanced radiotherapy services in India and we are trying to fill this gap by establishing a number of dedicated oncology centers closer to the Indian population over the next two years, the first of which is here in Noida. The focus of our company is to widen availability of a US-standard of cancer care to Indian patients."

"Current radiotherapy provision in India is nowhere near sufficient for a nation of over a billion people and advanced treatments tend to only be available in the major conurbations, which means people travel large distances and are inconvenienced during treatment. By providing this oncology centre in Noida and with our second facility due to open in Mumbai in three months, we feel we can make a major difference to the treatment options for India's huge cancer population." There are fewer than 400 radiotherapy machines in India and almost half of these are outdated cobalt machines.    

Pradeep K. Jaisingh added, "Varian has technology that we believe offers our patients a superior treatment and we plan to build on our relationship with Varian going forward."

International Oncology's model is to equip, staff and run state-of-the-art oncology centers within existing hospitals. With eight such centers expected to open in India in the next two years, the group plans to follow this up by implementing a similar model in South America, South-East Asia and the Middle East in due course.

Jeff Marcus, head of Oncology Systems sales for Varian, says, "International Oncology has ambitious expansion plans and Varian is pleased to be supplying our advanced radiotherapy technology for their growing number of oncology centers."

Varian has also supplied a full suite of brachytherapy equipment and software at Fortis International Oncology Centre.

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,000 people who are located at manufacturing sites in North America, Europe, and China and approximately 79 sales and support offices around the world. For more information, visit http://www.varian.com.


'/>"/>
SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016   Arena Pharmaceuticals, Inc. (NASDAQ: ... enrollment in the ralinepag phase 2 trial.  Ralinepag is ... pathway for the treatment of pulmonary arterial hypertension (PAH). ... "This marks an important step in the ... focus on our pipeline," said Amit Munshi , ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 According to ... in more than one-third (38%) of patients with non-small cell ... epidermal growth factor receptor (EGFR) genetic mutation status. The findings ... ( LBA ID #6067 #P3.02b ) at the ... Vienna, Austria . The survey results revealed ...
(Date:12/7/2016)... 7,2016  Based on its recent analysis ... & Sullivan recognizes Nemaura Pharma Limited with ... for Enabling Technology Leadership. Nemaura Pharma,s transdermal ... traditional drug delivery technologies, especially in delivering ... delivery technologies, Memspatch and Micropatch respectively, facilitate ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on his ... the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family ... hospital’s 30th heart transplant recipient. , “He was playing at home, when we got ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... One ... regular changing of the securement tape is painful for her. "This is why the ... to patients’ heads," she said. , They then created a prototype of the patent-pending ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic and ... website, which launched October 17, 2016, features comprehensive information regarding a wide range ... Visitors and patients can discover the latest clinical dermatology treatments for medical skin ...
(Date:12/7/2016)... ... , ... The medical profession is well aware that heart attacks do indeed ... heart attacks among 138,602 people recorded a 35% higher number of heart attacks in ... of course–no time of year is a good time for a heart attack! In ...
(Date:12/7/2016)... ... December 07, 2016 , ... “The Road To Restoration”: ... trial, not a one hour a week showing of hands. “The Road To Restoration” ... begins, “Perhaps you are familiar with the brass ring that you could reach out ...
Breaking Medicine News(10 mins):